Qing Song (6931) reported revenue of NT$114.4 million for Oct 2026, +17.0% year on year and +3.1% from the previous month. Revenue for Jan–Oct 2026 was NT$1.08 billion (+17.1% year on year).
Revenue for Oct 2026 was a record high (previous high: Jul 2026, NT$112.4 million). →
Year-on-year revenue growth: 25+ months in a row. →
In Oct 2026, it ranked No. 66 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$114.4 million | +17.0% | +3.1% |
| Sep 2026 | NT$110.9 million | +10.9% | -1.0% |
| Aug 2026 | NT$112.1 million | +19.0% | -0.3% |
| Jul 2026 | NT$112.4 million | +24.5% | +1.8% |
| Jun 2026 | NT$110.4 million | +18.8% | +0.8% |
| May 2026 | NT$109.6 million | +14.6% | +3.6% |
| Apr 2026 | NT$105.7 million | +12.7% | -3.7% |
| Mar 2026 | NT$109.8 million | +22.2% | +22.5% |
| Feb 2026 | NT$89.6 million | +6.4% | -14.8% |
| Jan 2026 | NT$105.2 million | +25.3% | +3.0% |
| Dec 2025 | NT$102.2 million | +15.0% | +5.5% |
| Nov 2025 | NT$96.9 million | +13.6% | -0.9% |
| Oct 2025 | NT$97.8 million | +18.8% | -2.3% |
| Sep 2025 | NT$100 million | +16.7% | +6.2% |
| Aug 2025 | NT$94.2 million | +9.0% | +4.3% |
| Jul 2025 | NT$90.3 million | +9.4% | -2.8% |
| Jun 2025 | NT$92.9 million | +13.6% | -2.9% |
| May 2025 | NT$95.7 million | +14.3% | +2.0% |
| Apr 2025 | NT$93.8 million | +18.0% | +4.4% |
| Mar 2025 | NT$89.8 million | +13.9% | +6.6% |
| Feb 2025 | NT$84.3 million | +19.4% | +0.4% |
| Jan 2025 | NT$83.9 million | +8.8% | -5.5% |
| Dec 2024 | NT$88.8 million | +14.1% | +4.1% |
| Nov 2024 | NT$85.3 million | +10.6% | +3.6% |
| Oct 2024 | NT$82.3 million | +3.4% | -4.0% |
Jan–Oct 2026 cumulative: NT$1.08 billion (+17.1% YoY)
Other Biotech & Medical companies
Compare with peers: Qing Song vs PEC / Qing Song vs Lotus Pharm / Qing Song vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16